ALX Oncology’s Evorpacept Shows Durable Responses in HER2-Positive Breast Cancer
Event summary
- Phase 1b/2 trial data show 100% response rate in HER2-positive breast cancer patients with high CD47 expression when treated with evorpacept and zanidatamab.
- Patients with high CD47 expression had a median progression-free survival of 22.1 months compared to 3.4 months for those with low CD47 expression.
- ALX Oncology will host a webcast on May 8, 2026, to discuss Q1 financial results and trial data.
- The trial included heavily pre-treated patients, all of whom had received prior ENHERTU therapy.
The big picture
ALX Oncology’s data suggest a potential breakthrough in treating heavily pre-treated HER2-positive breast cancer patients, leveraging a biomarker-driven approach to optimize treatment response. The results align with broader industry trends toward personalized medicine and combination therapies in oncology. The success of evorpacept in this setting could position ALX Oncology as a key player in the immuno-oncology space, particularly if the biomarker strategy proves applicable across multiple cancer types.
What we're watching
- Biomarker Validation
- Whether CD47 expression can be reliably used to predict response to evorpacept combinations in other cancer types.
- Regulatory Pathway
- The pace at which ALX Oncology advances evorpacept into later-stage trials and potential approvals.
- Competitive Positioning
- How ALX Oncology differentiates evorpacept from other CD47 inhibitors in the immuno-oncology space.
Related topics